VEGFA and non-Hodgkin lymphoma: To date, two of our NIC molecules containing PTX nanoparticles (modified nab-PTX) coated with bevacizumab (anti-VEGF) and a PTX-containing nanoparticle coated with rituximab (anti-CD20) have completed phase I clinical testing in heavily pretreated patients with relapsed/refractory metastatic gynecological malignancies and non-Hodgkin’s lymphoma.